Profile data is unavailable for this security.
About the company
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The Company provides medical device products and systems for use in both hospital and homecare settings. Its hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include its continuous positive airway pressure (CPAP) therapy masks as well as flow generators, interfaces, and data management technologies. The Company’s products are sold in over 120 countries worldwide. It operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, and others.
- Revenue in NZD (TTM)2.02bn
- Net income in NZD377.20m
- Incorporated1954
- Employees7.51k
- LocationFisher & Paykel Healthcare Corporation Ltd15 Maurice Paykel Place, East Tamaki,AUCKLAND 2013New ZealandNZL
- Phone+64 95740100
- Fax+64 95740158
- Websitehttps://www.fphcare.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sysmex Corp | 5.77bn | 608.83m | 17.78bn | 10.53k | 28.93 | 3.35 | 16.92 | 3.08 | 86.07 | 86.07 | 815.75 | 743.71 | 0.7922 | 2.94 | 3.09 | 48,290,420.00 | 8.34 | 8.70 | 10.29 | 10.94 | 53.47 | 52.47 | 10.53 | 10.98 | 2.30 | 10.86 | 0.1235 | 38.11 | 10.21 | 10.99 | 8.12 | 9.00 | 13.54 | 5.92 |
| Fisher & Paykel Healthcare Corporatn Ltd | 2.02bn | 377.20m | 21.55bn | 7.51k | 57.52 | 11.39 | 41.67 | 10.66 | 0.6389 | 0.6389 | 3.42 | 3.23 | 0.8364 | 2.26 | 7.19 | 269,251.30 | 15.61 | 15.58 | 19.11 | 18.80 | 62.88 | 61.70 | 18.66 | 18.46 | 1.18 | 80.89 | 0.075 | 58.59 | 15.96 | 9.85 | 184.46 | 5.60 | -9.61 | 9.10 |
| Cochlear Ltd | 2.53bn | 405.29m | 21.97bn | 5.00k | 54.44 | 10.76 | 44.04 | 8.70 | 5.64 | 5.64 | 35.15 | 28.54 | 0.8686 | 1.43 | 4.87 | 461,780.00 | 13.94 | 8.55 | 17.76 | 11.15 | 75.75 | 75.05 | 16.05 | 11.98 | 1.52 | -- | 0.1166 | 91.14 | 15.47 | 9.40 | 18.70 | 5.22 | -4.76 | 4.44 |
| Olympus Corp | 11.31bn | 1.34bn | 22.21bn | 29.30k | 16.66 | 2.58 | 10.63 | 1.96 | 103.21 | 103.27 | 870.68 | 666.54 | 0.6723 | 1.66 | 4.96 | 34,042,120.00 | 7.94 | 6.74 | 11.17 | 9.51 | 68.55 | 66.85 | 11.81 | 10.69 | 1.16 | 63.11 | 0.2336 | 21.13 | 6.53 | 5.72 | 342.69 | 14.22 | -0.2194 | 14.87 |
| Shanghai United Img Hlthcare Co Ltd | 2.45bn | 297.72m | 24.49bn | 8.17k | 81.86 | 5.15 | -- | 10.01 | 1.55 | 1.55 | 12.73 | 24.61 | 0.3848 | 1.04 | 2.39 | 1,275,857.00 | 4.60 | 8.24 | 6.05 | 11.87 | 48.07 | 48.34 | 11.94 | 16.40 | 2.00 | -- | 0.0595 | 7.41 | -9.73 | 28.16 | -36.08 | -- | 24.57 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Hyperion Asset Management Ltd.as of 27 Feb 2025 | 28.70m | 4.90% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 21.18m | 3.61% |
| First Sentier Investors (Australia) IM Ltd.as of 28 Feb 2025 | 14.69m | 2.51% |
| Guardians of New Zealand Superannuationas of 30 Jun 2023 | 13.09m | 2.23% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 10.85m | 1.85% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 10.05m | 1.72% |
| First Sentier Investors (Hong Kong) Ltd.as of 28 Feb 2025 | 6.82m | 1.16% |
| Geode Capital Management LLCas of 10 Jul 2025 | 6.32m | 1.08% |
| First Sentier Investors (Singapore)as of 28 Feb 2025 | 6.24m | 1.07% |
| Smartshares Ltd.as of 30 May 2025 | 5.09m | 0.87% |
